Sophiris plummets on doubts its prostate drug can clear Phase III

December 15, 2014 4:05 PM

14 0

Taking an early look at data from an ongoing study of Sophiris Bio's ($SPHS) lead drug, independent advisers say the prostate-shrinking therapy didn't meet its predefined threshold for efficacy, casting a shadow over the biotech's only clinical asset.

The drug, PRX302, is in the midst of a 52-week trial on 479 patients to determine how well it can treat lower urinary tract symptoms of benign prostatic hyperplasia, or enlarged prostate. In a scheduled look at results, the trial's data monitoring committee reported that PRX302 wasn't performing as ...

Read more

To category page